GSK Links With OncoMed, Galapagos To Boost Oncologic, Anti-Infective Pipelines
Deals present possible $1.4 billion for OncoMed, €245 million for Galapagos through GSK’s external drug discovery centers.
Deals present possible $1.4 billion for OncoMed, €245 million for Galapagos through GSK’s external drug discovery centers.